ClinicalTrials.gg
Not yet recruitingNCT07618858CITRA-HDFUpdated Jun 1, 2026

Comparison of Citrate and Heparin Anticoagulation During Postdilution Hemodiafiltration

An interventional study of Regional citrate anticoagulation and Unfractionated heparin in End-Stage Kidney Disease, Hemodiafiltration and Chronic Hemodialysis, sponsored by University Medical Centre Ljubljana. Not yet recruiting at 1 site in Slovenia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by University Medical Centre Ljubljana · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Kidney Failure, Chronic with a site in Slovenia — 2 open to participants now, 2 under way, none of them phase 3. Kidney Failure, Chronic · Slovenia.

Planned enrollment
10th of 11
20 · median 50
Started
2026
the only one that year
No phase
8 of 13
1 open now
Registered
13th of 13
by date
Lead sponsor
6 of 13
University Medical Centre Ljubljana

Among the 13 studies in Kidney Failure, Chronic with a site in Slovenia, this one is the 10th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2026, is one of 8 with no phase, and was the 13th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

2 of the 13 studies in Kidney Failure, Chronic with a site in Slovenia are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Slovenia have not opened yet or have stopped. Only those recruiting at a site in Slovenia →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Kidney Failure, Chronic with a site in Slovenia, or all of them as a file.
02

Study summary

This randomized crossover clinical trial will compare regional citrate anticoagulation (RCA) and standard heparin anticoagulation (HA) during postdilution hemodiafiltration (HDF) in chronic dialysis patients with end-stage kidney disease.

The primary aim of the study is to evaluate biocompatibility during HDF by measuring markers of complement activation (C3a), platelet activation (PF4), and coagulation activation (thrombin-antithrombin complex, TAT).

Secondary aims include comparison of solute removal efficiency, including beta-2 microglobulin, phosphate, and urea removal, as well as assessment of citrate, calcium, and magnesium kinetics during citrate anticoagulation.

Twenty adult chronic dialysis patients will undergo two study HDF procedures in randomized order: one procedure using heparin anticoagulation and one procedure using regional citrate anticoagulation with a one-week interval between procedures.

The study aims to improve understanding of the effects of anticoagulation methods on hemodiafiltration biocompatibility and dialysis efficiency and may contribute to optimization of citrate anticoagulation protocols in chronic hemodiafiltration patients.

Read the detailed description

Hemodiafiltration (HDF) is an advanced renal replacement therapy combining diffusion and convection, allowing improved removal of middle and larger molecular weight solutes compared with standard hemodialysis. During extracorporeal circulation, blood contact with artificial membranes and tubing activates complement, platelets, leukocytes, and coagulation pathways, requiring anticoagulation during the procedure.

Unfractionated heparin is routinely used for anticoagulation during HDF. Regional citrate anticoagulation (RCA) is mainly used in patients at increased bleeding risk. Previous studies in hemodialysis have suggested that citrate anticoagulation may improve biocompatibility because many blood-material interactions are calcium- and magnesium-dependent. However, biocompatibility during HDF using citrate versus heparin anticoagulation has not been systematically investigated.

This prospective randomized crossover clinical trial will include 20 adult patients with end-stage kidney disease receiving maintenance postdilution hemodiafiltration three times weekly. Patients will be randomized to one of two anticoagulation sequences: heparin-citrate or citrate-heparin. Each participant will undergo two study HDF procedures separated by a one-week interval.

During heparin anticoagulation, unfractionated heparin will be administered according to body weight using standard clinical protocols. During citrate anticoagulation, 8% trisodium citrate infusion and calcium-free dialysate will be used, with continuous calcium chloride substitution adjusted according to ionized calcium levels.

Biocompatibility markers including complement activation marker C3a, platelet factor 4 (PF4), thrombin-antithrombin complex (TAT), blood cell counts, and coagulation parameters will be assessed before HDF, after 15 minutes, and at the end of the procedure.

Dialysis efficiency will be evaluated by measurement of reduction ratios and total removal of beta-2 microglobulin, phosphate, and urea using partial dialysate collection methodology.

Additional secondary outcomes include assessment of citrate, calcium, and magnesium kinetics during RCA-HDF, visual clotting score evaluation of the extracorporeal circuit, and optimization of citrate anticoagulation protocols during postdilution HDF.

The study may contribute to improved understanding of anticoagulation-related biocompatibility during HDF and support wider evidence-based use of regional citrate anticoagulation in chronic dialysis patients.

03

Conditions studied

  • End-Stage Kidney Disease
  • Hemodiafiltration
  • Chronic Hemodialysis
  • Renal Failure

Keywords

  • Citrate anticoagulation
  • Heparin anticoagulation
  • Hemodiafiltration
  • Dialysis
  • Biocompatibility
  • Beta-2 microglobulin
  • Complement activation
  • Regional citrate anticoagulation
  • Chronic dialysis
  • Thrombin-antithrombin complex
  • Platelet factor 4
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older
  • End-stage kidney disease requiring maintenance postdilution hemodiafiltration
  • Stable chronic hemodialysis treatment three times weekly
  • Functional arteriovenous fistula

Exclusion criteria

Exclusion Criteria:

  • Therapeutic anticoagulation therapy
  • Dual antiplatelet therapy
  • Significant coagulopathy
  • Active bleeding
  • Acute kidney injury
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Citrate anticoagulation

    Participants will undergo postdilution hemodiafiltration using regional citrate anticoagulation with 8% trisodium citrate infusion and calcium substitution according to ionized calcium measurements

    Drug: Regional citrate anticoagulation

  • Active comparator
    Heparin anticoagulation

    Participants will undergo postdilution hemodiafiltration using standard unfractionated heparin anticoagulation according to routine clinical protocol.

    Drug: Unfractionated heparin

Interventions

  • DrugRegional citrate anticoagulation

    Regional citrate anticoagulation using 8% trisodium citrate infusion during postdilution hemodiafiltration with calcium substitution adjusted according to ionized calcium levels.

  • DrugHeparinStudies of HeparinHeparin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Standard unfractionated heparin anticoagulation administered according to routine clinical protocol during postdilution hemodiafiltration.

06

What researchers measure

Primary outcomes

  1. Biocompatibility markers (C3a, PF4, TAT)

    Comparison of complement activation marker C3a, platelet factor 4 (PF4), and thrombin-antithrombin complex (TAT) concentrations between citrate and heparin anticoagulation during postdilution hemodiafiltration.

    Time frame: Before hemodiafiltration, after 15 minutes of treatment, and immediately before the end of the procedure.

Secondary outcomes

  1. Beta-2 microglobulin removal

    Reduction ratio and total removal of beta-2 microglobulin during hemodiafiltration.

    Time frame: Before, after 30 minutes and at the end of the procedure hemodiafiltration procedure.

  2. instantaneous urea clearance after 30 minutes

    instantaneous urea clearance after 30 minutes

    Time frame: after 30 minutes of dialysis

  3. p-cresyl sulfat removal

    P-cresyl sulfat removal before, after 30 minutes and at the end of the procedure

    Time frame: P-cresyl sulfat removal before, during and to the end of procedure

  4. Ionized calcium kinetics

    During citrate anticoagulation procedure

    Time frame: During the 4-hour hemodiafiltration procedure

  5. Extracorporeal circuit clotting score

    Time frame: At the end of hemodiafiltration procedure.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be publicly available due to privacy and institutional data protection regulations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Dec 2026, 6 months later.

Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 6 months is below that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2026
First posted
Jun 1, 2026
StartEst.
Jun 5, 2026
Primary completionEst.
Dec 15, 2026
CompletionEst.
Apr 1, 2027
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07618858
Responsible party
Milena Andonova (Principal Investigator, Department of Nephrology, University Medical Centre Ljubljana) — Principal investigator
First posted
Jun 1, 2026
Start date
Jun 5, 2026 (estimated)
Primary completion
Dec 15, 2026 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Jun 1, 2026

Study contacts

Milena MD Andonova
Contact
milena.andonova@kclj.si
+38615228123

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion